International Journal of Radiation Oncology * Biology * Physics
Volume 78, Issue 1 , Pages 35-41 , 1 September 2010

Expression of Bcl-2, p53, and MDM2 in Localized Prostate Cancer With Respect to the Outcome of Radical Radiotherapy Dose Escalation

  • Roy Vergis, M.D.

      Affiliations

    • Academic Urology Unit, Institute of Cancer Research, Royal Marsden NHS Foundation Trust, Surrey, UK
    • ,
  • Catherine M. Corbishley, M.D.

      Affiliations

    • Department of Cellular Pathology, St. George's Hospital, Tooting, UK
    • ,
  • Karen Thomas, B.Sc.

      Affiliations

    • Statistics, Royal Marsden NHS Foundation Trust, Surrey, UK
    • ,
  • Alan Horwich, M.D., Ph.D.

      Affiliations

    • Academic Urology Unit, Institute of Cancer Research, Royal Marsden NHS Foundation Trust, Surrey, UK
    • ,
  • Robert Huddart, M.D., Ph.D.

      Affiliations

    • Academic Urology Unit, Institute of Cancer Research, Royal Marsden NHS Foundation Trust, Surrey, UK
    • ,
  • Vincent Khoo, M.D.

      Affiliations

    • Academic Urology Unit, Institute of Cancer Research, Royal Marsden NHS Foundation Trust, Surrey, UK
    • ,
  • Ros Eeles, M.D., Ph.D.

      Affiliations

    • Academic Urology Unit, Institute of Cancer Research, Royal Marsden NHS Foundation Trust, Surrey, UK
    • ,
  • Matthew R. Sydes, B.Sc.

      Affiliations

    • Medical Research Council Clinical Trials Unit, London, UK
    • ,
  • Colin S. Cooper, Ph.D.

      Affiliations

    • Academic Urology Unit, Institute of Cancer Research, Royal Marsden NHS Foundation Trust, Surrey, UK
    • ,
  • David Dearnaley, M.D.

      Affiliations

    • Academic Urology Unit, Institute of Cancer Research, Royal Marsden NHS Foundation Trust, Surrey, UK
    • ,
  • Chris Parker, M.D.

      Affiliations

    • Academic Urology Unit, Institute of Cancer Research, Royal Marsden NHS Foundation Trust, Surrey, UK
    • Corresponding Author InformationReprint requests to: Dr. Chris Parker, M.D., Academic Unit of Radiotherapy & Oncology, Institute of Cancer Research, Downs Road, Sutton, Surrey, SM2 5PT, UK. Tel: (+44) 0-020-8661-3425; Fax: (+44) 0-020-8643-8809

Received 7 April 2009 ,Revised 10 July 2009 ,Accepted 16 July 2009.

References 

  1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin. 2006;56:106–130
  2. Albertsen PC, Hanley JA, Fine J. 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA. 2005;293:2095–2101
  3. Cuzick J, Fisher G, Kattan MW, et al. Long-term outcome among men with conservatively treated localised prostate cancer. Br J Cancer. 2006;95:1186–1194
  4. Stephenson AJ, Scardino PT, Eastham JA, et al. Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Natl Cancer Inst. 2006;98:715–717
  5. Kuban DA, Tucker SL, Dong L, et al. Long-term results of the M.D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys. 2008;70:67–74
  6. Peeters ST, Heemsbergen WD, Koper PC, et al. Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol. 2006;24:1990–1996
  7. Dearnaley DP, Sydes MR, Graham JD, et al. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: First results from the MRC RT01 randomised controlled trial. Lancet Oncol. 2007;8:475–487
  8. Denmeade S, Isaacs J. Activation of programmed (apoptotic) cell death for the treatment of prostate cancer. Adv Pharmacol. 1996;35:–306
  9. Szostak MJ, Kyprianou N. Radiation-induced apoptosis: predictive and therapeutic significance in radiotherapy of prostate cancer (review). Oncol Rep. 2000;7:699–706
  10. McDonnell TJ, Troncoso P, Brisbay SM, et al. Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res. 1992;52:6940–6944
  11. Bauer JJ, McLeod DG, Moul JW. Prostate cancer: Diagnosis, treatment, and experience at one tertiary-care military medical center, 1989 and 1994. Mil Med. 1996;161:646–653
  12. Krajewska M, Krajewski S, Epstein JI, et al. Immunohistochemical analysis of bcl-2, bax, bcl-X, and mcl-1 expression in prostate cancers. Am J Pathol. 1996;148:1567–1576
  13. Autorino R, Di Lorenzo G, Damiano R, et al. Role of chemotherapy in hormone-refractory prostate cancer: Old issues, recent advances and new perspectives. Urol Int. 2003;70:1–14
  14. Shaffer DR, Scher HI. Prostate cancer: A dynamic illness with shifting targets. Lancet Oncol. 2003;4:407–414
  15. Rosser CJ, Reyes AO, Vakar-Lopez F, et al. Bcl-2 is significantly overexpressed in localized radio-recurrent prostate carcinoma, compared with localized radio-naive prostate carcinoma. Int J Radiat Oncol Biol Phys. 2003;56:1–6
  16. Krajewska M, Moss SF, Krajewski S, et al. Elevated expression of Bcl-X and reduced Bak in primary colorectal adenocarcinomas. Cancer Res. 1996;56:2422–2427
  17. Hering FL, Lipay MV, Lipay MA, et al. Comparison of positivity frequency of bcl-2 expression in prostate adenocarcinoma with low and high Gleason score. Sao Paulo Med J. 2001;119:138–141
  18. Colombel M, Symmans F, Gil S, et al. Detection of the apoptosis-suppressing oncoprotein bc1-2 in hormone-refractory human prostate cancers. Am J Pathol. 1993;143:390–400
  19. Mu Z, Hachem P, Pollack A. Antisense Bcl-2 sensitizes prostate cancer cells to radiation. Prostate. 2005;65:331–340
  20. An J, Chervin AS, Nie A, Ducoff HS, et al. Overcoming the radioresistance of prostate cancer cells with a novel Bcl-2 inhibitor. Oncogene. 2007;26:652–661
  21. Pollack A, Cowen D, Troncoso P, et al. Molecular markers of outcome after radiotherapy in patients with prostate carcinoma: Ki-67, bcl-2, bax, and bcl-x. Cancer. 2003;97:1630–1638
  22. Mackey TJ, Borkowski A, Amin P, et al. bcl-2/bax ratio as a predictive marker for therapeutic response to radiotherapy in patients with prostate cancer. Urology. 1998;52:1085–1090
  23. Bauer JJ, Sesterhenn IA, Mostofi FK, et al. Elevated levels of apoptosis regulator proteins p53 and bcl-2 are independent prognostic biomarkers in surgically treated clinically localized prostate cancer. J Urol. 1996;156:1511–1516
  24. Szostak MJ, Kaur P, Amin P, Jacobs SC, et al. Apoptosis and bcl-2 expression in prostate cancer: significance in clinical outcome after brachytherapy. J Urol. 2001;165(Pt 1):2126–2130
  25. Scherr DS, Vaughan ED, Wei J, et al. BCL-2 and p53 expression in clinically localized prostate cancer predicts response to external beam radiotherapy. J Urol. 1999;162:12–16discussion 16–17
  26. Khor LY, Moughan J, Al-Saleem T, et al. Bcl-2 and Bax expression predict prostate cancer outcome in men treated with androgen deprivation and radiotherapy on radiation therapy oncology group protocol 92-02. Clin Cancer Res. 2007;13:3585–3590
  27. Khor LY, Desilvio M, Li R, et al. Bcl-2 and bax expression and prostate cancer outcome in men treated with radiotherapy in Radiation Therapy Oncology Group protocol 86-10. Int J Radiat Oncol Biol Phys. 2006;66:25–30
  28. Bylund A, Stattin P, Widmark A, et al. Predictive value of bcl-2 immunoreactivity in prostate cancer patients treated with radiotherapy. Radiother Oncol. 1998;49:143–148
  29. Vogelstein B, Kinzler KW. p53 function and dysfunction. Cell. 1992;70:523–526
  30. Kirsch DG, Kastan MB. Tumor-suppressor p53: implications for tumor development and prognosis. J Clin Oncol. 1998;16:3158–3168
  31. Ritter MA, Gilchrist KW, Voytovich M, et al. The role of p53 in radiation therapy outcomes for favorable-to-intermediate-risk prostate cancer. Int J Radiat Oncol Biol Phys. 2002;53:574–580
  32. Grignon DJ, Caplan R, Sarkar FH, et al. p53 status and prognosis of locally advanced prostatic adenocarcinoma: A study based on RTOG 8610. J Natl Cancer Inst. 1997;89:158–165
  33. Che M, DeSilvio M, Pollack A, et al. Prognostic value of abnormal p53 expression in locally advanced prostate cancer treated with androgen deprivation and radiotherapy: A study based on RTOG 9202. Int J Radiat Oncol Biol Phys. 2007;69:1117–1123
  34. Momand J, Zambetti GP, Olson DC, et al. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell. 1992;69:1237–1245
  35. Leite KR, Franco MF, Srougi M, et al. Abnormal expression of MDM2 in prostate carcinoma. Mod Pathol. 2001;14:428–436
  36. Agus DB, Cordon-Cardo C, Fox W, et al. Prostate cancer cell cycle regulators: response to androgen withdrawal and development of androgen independence. J Natl Cancer Inst. 1999;91:1869–1876
  37. Khor LY, Desilvio M, Al-Saleem T, et al. MDM2 as a predictor of prostate carcinoma outcome: An analysis of Radiation Therapy Oncology Group Protocol 8610. Cancer. 2005;104:962–967
  38. Sydes MR, Stephens RJ, Moore AR, et al. Implementing the UK Medical Research Council (MRC) RT01 trial (ISRCTN 47772397): Methods and practicalities of a randomised controlled trial of conformal radiotherapy in men with localised prostate cancer. Radiother Oncol. 2004;72:199–211
  39. Dearnaley DP, Hall E, Lawrence D, et al. Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects. Br J Cancer. 2005;92:488–498
  40. Jhavar S, Corbishley CM, Dearnaley D, et al. Construction of tissue microarrays from prostate needle biopsy specimens. Br J Cancer. 2005;93:478–482
  41. Stoyanova R, Hachem P, Hensley H, et al. Antisense-MDM2 sensitizes LNCaP prostate cancer cells to androgen deprivation, radiation, and the combination in vivo. Int J Radiat Oncol Biol Phys. 2007;68:1151–1160
  42. Anai S, Goodison S, Shiverick K, et al. Knock-down of Bcl-2 by antisense oligodeoxynucleotides induces radiosensitization and inhibition of angiogenesis in human PC-3 prostate tumor xenografts. Mol Cancer Ther. 2007;6:101–111
  43. Vergis R, Corbishley CM, Norman AR, et al. Intrinsic markers of tumour hypoxia and angiogenesis in localised prostate cancer and outcome of radical treatment: A retrospective analysis of two randomised radiotherapy trials and one surgical cohort study. Lancet Oncol. 2008;9:342–351

 Supported by the Institute of Cancer Research, the Cancer Research UK Section of Radiotherapy [CUK] grant number C46/A2131, the NCRI South of England Prostate Cancer Collaborative, and the Grand Charity of Freemasons. The authors acknowledge NHS funding to the NIHR Biomedical Research Centre. This work was undertaken in The Royal Marsden NHS Foundation Trust, which received a proportion of its funding from the NHS Executive; the views expressed in this publication are those of the authors and not necessarily those of the NHS Executive.

 Conflict of interest: none.

PII: S0360-3016(09)02921-6

doi: 10.1016/j.ijrobp.2009.07.1728

International Journal of Radiation Oncology * Biology * Physics
Volume 78, Issue 1 , Pages 35-41 , 1 September 2010

Article Tools

* Image Usage & Resolution